- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | H.C. Wainwright reiterates Aura Biosciences stock rating at buy | 4 | Investing.com | ||
| 30.03. | Aura Biosciences GAAP EPS of -$1.76 beats by $0.19 | 3 | Seeking Alpha | ||
| 30.03. | Aura Biosciences, Inc.: Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | 110 | GlobeNewswire (Europe) | Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month... ► Artikel lesen | |
| 30.03. | Aura Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Aura Biosciences, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Aura Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Evercore ISI nimmt Coverage für Aura Biosciences mit "Outperform" wieder auf | 9 | Investing.com Deutsch | ||
| AURA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | Evercore ISI resumes Aura Biosciences stock coverage with Outperform rating | 2 | Investing.com | ||
| 13.11.25 | Aura Biosciences GAAP EPS of -$0.40 beats by $0.07 | 4 | Seeking Alpha | ||
| 13.11.25 | Aura Biosciences, Inc.: Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights | 279 | GlobeNewswire (Europe) | Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar's Potential... ► Artikel lesen | |
| 13.11.25 | Aura Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | Aura Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08.25 | Aura Biosciences, Inc.: Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights | 371 | GlobeNewswire (Europe) | Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with... ► Artikel lesen | |
| 15.05.25 | Aura Biosciences, Inc.: Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights | 509 | GlobeNewswire (Europe) | First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,95 | +2,07 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| AMGEN | 296,60 | -0,29 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 6,940 | +0,73 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 152,26 | +1,48 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| REGENERON PHARMACEUTICALS | 640,90 | +0,98 % | Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU | DJ Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU
Von Colin Kellaher
DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,200 | +1,34 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,560 | +10,72 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INTELLIA THERAPEUTICS | 12,580 | +3,80 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 41,375 | +5,83 % | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,000 | -0,07 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,520 | 0,00 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,920 | +2,27 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| EXELIXIS | 39,055 | +2,14 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,290 | +4,20 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,200 | +2,92 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart | Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the... ► Artikel lesen |
AURA BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,195 (+2,83 %) liegt der Kurs bei 7,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AURA BIOSCIENCES INC finden Sie auf Wallstreet Online.